These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 26031830)

  • 1. Next-Generation Therapeutics for IBD.
    Löwenberg M; D'Haens G
    Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins].
    Kim KO; Lee SH
    Korean J Gastroenterol; 2024 Aug; 84(2):43-50. PubMed ID: 39176460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel treatments for inflammatory bowel disease.
    Lee HS; Park SK; Park DI
    Korean J Intern Med; 2018 Jan; 33(1):20-27. PubMed ID: 29223139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Emerging Therapies: What Are Promising in the Near Future?].
    Seo GS; Lee SH
    Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatment options for inflammatory bowel diseases.
    Verstockt B; Ferrante M; Vermeire S; Van Assche G
    J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: anti-adhesion therapies for inflammatory bowel disease.
    Lobatón T; Vermeire S; Van Assche G; Rutgeerts P
    Aliment Pharmacol Ther; 2014 Mar; 39(6):579-94. PubMed ID: 24479980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A product review of vedolizumab in inflammatory bowel disease.
    Battat R; Dulai PS; Jairath V; Vande Casteele N
    Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where are we heading to in pharmacological IBD therapy?
    Rogler G
    Pharmacol Res; 2015 Oct; 100():220-7. PubMed ID: 26277232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
    Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
    Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.
    Sommer K; Heidbreder K; Kreiss L; Dedden M; Paap EM; Wiendl M; Becker E; Atreya R; Müller TM; Atreya I; Waldner M; Schürmann S; Friedrich O; Neurath MF; Zundler S
    Clin Transl Med; 2023 Apr; 13(4):e1233. PubMed ID: 37029786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.